NASDAQ: HURA
Tuhura Biosciences Inc Stock Forecast, Predictions & Price Target

Analyst price target for HURA

Based on 1 analyst offering 12 month price targets for Tuhura Biosciences Inc

Min Forecast
$10.00+1,769.16%
Avg Forecast
$10.00+1,769.16%
Max Forecast
$10.00+1,769.16%

Should I buy or sell HURA stock?

Based on 1 analyst offering ratings for Tuhura Biosciences Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although HURA's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates HURA as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their HURA stock forecasts and price targets.

HURA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-01-09
lockedlocked$00.00+00.00%2025-11-14

1 of 1

Forecast return on equity

Is HURA forecast to generate an efficient return?

Company
291.36%
Industry
352.12%
Market
211.34%
HURA's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is HURA forecast to generate an efficient return on assets?

Company
190.24%
Industry
122.26%
HURA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

HURA earnings per share forecast

What is HURA's earnings per share in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
-$0.51-204.08%
Avg 2 year Forecast
-$0.59-220.73%
Avg 3 year Forecast
$0.05-89.59%

HURA revenue forecast

What is HURA's revenue in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$23.0M
Avg 3 year Forecast
$21.4M

HURA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
HURA$0.54$10.00+1,769.16%Buy
RLYB$0.64N/AN/A
MRKR$1.60$10.00+525.00%Buy
OTLK$0.44$3.83+771.14%Hold
NERV$4.06$4.00-1.48%Hold

Tuhura Biosciences Stock Forecast FAQ

Is Tuhura Biosciences Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: HURA) stock is to Buy HURA stock.

Out of 1 analyst, 0 (0%) are recommending HURA as a Strong Buy, 1 (100%) are recommending HURA as a Buy, 0 (0%) are recommending HURA as a Hold, 0 (0%) are recommending HURA as a Sell, and 0 (0%) are recommending HURA as a Strong Sell.

If you're new to stock investing, here's how to buy Tuhura Biosciences stock.

What is HURA's earnings growth forecast for 2026-2028?

(NASDAQ: HURA) Tuhura Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 69.84%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.88%.

Tuhura Biosciences's earnings in 2026 is -$33,663,123.On average, 6 Wall Street analysts forecast HURA's earnings for 2026 to be -$26,141,623, with the lowest HURA earnings forecast at -$27,628,108, and the highest HURA earnings forecast at -$24,219,445. On average, 5 Wall Street analysts forecast HURA's earnings for 2027 to be -$30,324,283, with the lowest HURA earnings forecast at -$29,135,096, and the highest HURA earnings forecast at -$31,216,174.

In 2028, HURA is forecast to generate $2,614,162 in earnings, with the lowest earnings forecast at -$22,102,486 and the highest earnings forecast at $29,063,334.

What is HURA's revenue growth forecast for 2026-2028?

(NASDAQ: HURA) Tuhura Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.92%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.08%.

Tuhura Biosciences's revenue in 2026 is $0.On average, 6 Wall Street analysts forecast HURA's revenue for 2026 to be $0, with the lowest HURA revenue forecast at $0, and the highest HURA revenue forecast at $0. On average, 5 Wall Street analysts forecast HURA's revenue for 2027 to be $1,179,704,826, with the lowest HURA revenue forecast at $0, and the highest HURA revenue forecast at $3,643,270,908.

In 2028, HURA is forecast to generate $1,098,768,310 in revenue, with the lowest revenue forecast at $1,055,711,519 and the highest revenue forecast at $1,131,112,162.

What is HURA's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: HURA) forecast ROA is 190.24%, which is higher than the forecast US Biotechnology industry average of 122.26%.

What is HURA's Price Target?

According to 1 Wall Street analyst that have issued a 1 year HURA price target, the average HURA price target is $10.00, with the highest HURA stock price forecast at $10.00 and the lowest HURA stock price forecast at $10.00.

The Wall Street analyst predicted that Tuhura Biosciences's share price could reach $10.00 by Jan 9, 2027. The average Tuhura Biosciences stock price prediction forecasts a potential upside of 1,769.16% from the current HURA share price of $0.54.

What is HURA's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: HURA) Tuhura Biosciences's current Earnings Per Share (EPS) is $0.49. On average, analysts forecast that HURA's EPS will be -$0.51 for 2026, with the lowest EPS forecast at -$0.54, and the highest EPS forecast at -$0.47. On average, analysts forecast that HURA's EPS will be -$0.59 for 2027, with the lowest EPS forecast at -$0.57, and the highest EPS forecast at -$0.61. In 2028, HURA's EPS is forecast to hit $0.05 (min: -$0.43, max: $0.57).

What is HURA's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: HURA) forecast ROE is 291.36%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.